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Changes in calf muscle deoxygenation after foam
sclerotherapy in patients with superficial venous
insufficiency
Takashi Yamaki, MD, Hisato Konoeda, MD, Daisuke Fujisawa, MD, Kota Ogino, MD,
Atsuyoshi Osada, MD, Atsumori Hamahata, MD, Motohiro Nozaki, MD, and
Hiroyuki Sakurai, MD, Tokyo, Japan
Objective: This study assessed changes in the calf muscle deoxygenated hemoglobin (HHb) level during light-intensity
exercise after ultrasound-guided foam sclerotherapy (UGFS) for superficial venous insufficiency.
Methods: UGFS with 1% or 3% polidocanol foam (POL-F) was used to treat unilateral great saphenous vein reflux in 84
patients. Near-infrared spectroscopy (NIRS) was used to measure calf muscle HHb levels before and 3 months after
UGFS. The calf venous HHb blood-filling index was calculated on standing, the calf venous HHb ejection index was
obtained after one tiptoe movement, and the venous HHb retention index was obtained after 10 tiptoe movements. The
primary end point was an evident improvement in calf muscle deoxygenation after UGFS. The secondary end point was
obliteration of the great saphenous vein.
Results: Treatment consisted of 1% POL-F in 48 limbs and 3% POL-F in the remaining 36. Ultrasound imaging at the
3-month follow-up demonstrated complete occlusion in 56.3% of the patients who received injections of 1% POL-F and
in 66.7% of those who received injections of 3% POL-F. The difference in treatment outcome between the groups was not
significant (P .333). Reflux was absent in 39 limbs (81.3%) treated with 1% POL-F and in 34 limbs (94.4%) treated with
3% POL-F, and no significant difference was observed between the two groups (P  .076). Postsclerotherapy NIRS
demonstrated significant reductions in the levels of theHHb filling index in both treatment groups (P .039, P .0001,
respectively) and significant reductions in the levels of the HHb retention index (P < .0001, P  .008, respectively).
However, the differences in the levels of the HHb ejection index before and after UGFS were not significant (P  .250,
P  .084, respectively).
Conclusions:Our present findings suggest that changes in the values of these parameters may be of potential use for assessing
the effects of foam sclerotherapy in patients with superficial venous insufficiency. (J Vasc Surg 2012;56:1649-55.)
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bRecent advances in the field of phlebology have led to a
decrease in the use of invasive techniques for the diagnosis
of chronic venous insufficiency (CVI). Duplex ultrasound
scanning augmented by color-flow Doppler imaging has
been developed over the last 2 decades and has almost
replaced invasive venography. An ultrasound-derived reflux
time (RT) of 0.5 seconds has been used as the gold
standard for evaluation of venous reflux.1-3 However, re-
cent studies have shown that peak reflux velocity (PRV)
better correlates with the clinical severity of CVI than
individual or total RT.4-9
Near-infrared spectroscopy (NIRS) is a noninvasive
optical method that was developed for determining tissue
oxygenation and hemodynamics. Using a modification of
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http://dx.doi.org/10.1016/j.jvs.2012.03.266he Lambert-Beer law,10 it is now possible to obtain quan-
itative values for the levels of total hemoglobin (Hb),
xygenated hemoglobin (O2Hb), and deoxygenated he-
oglobin (HHb). NIRS measurements primarily reflect
hanges in the small arterioles, capillaries, and venules.11
everal investigators have demonstrated a correlation be-
ween the severity of CVI and changes in HHb and showed
hat NIRS might be useful for assessment of ambulatory
enous function in patients with CVI.12-14
Huge advances have also been made in the manage-
ent of venous diseases. Invasive stripping operations have
radually been replaced by endogenous thermal and chem-
cal ablations that can reduce operative morbidity and re-
overy time. Although ultrasound-guided foam sclerother-
py (UGFS) has been recognized as a common treatment
ption for patients with superficial CVI, no studies have
ttempted to define the relationship between the changes
n HHb and clinical improvement after UGFS. The pur-
ose of the present study was to define how foam sclero-
herapy for superficial CVI affects the values of parameters
etermined by NIRS in the lower extremities.
ETHODS
The UGFS treatment used in this study was approved
y the Institutional Review Board, and informed consent
as obtained from all participants.
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December 20121650 Yamaki et alPatients. The study comprised 84 patients (24 men;
60 women), with a mean age of 65.4 years (range, 45-82
years), who were treated for great saphenous vein (GSV)
reflux associated with saphenofemoral junction (SFJ) in-
competence between March 2010 and June 2010. Among
the 84 patients, 48 received UGFS using 1% polidocanol
foam (POL-F), and the remaining 36 received UGFS using
3% POL-F. Patients’ height, weight, and body mass index
(kg/m2) were recorded, as well as CEAP scores.15 All
patients examined in this study were classified as C2,3,4a, Ep,
As, Pr2,3. The study excluded patients with myocardial
ischemia, arterial insufficiency, those with an ankle-brachial
index of 0.9, in the first trimester of pregnancy and after
the 36th week of gestation, local infection in the area
scheduled for sclerotherapy, active thrombophlebitis, and
acute deep vein thrombosis.
Pretreatment evaluation. Pretreatment venous reflux
examination was performed using a color duplex scanner
(LOGIQ 7 PRO; GE Healthcare, Japan, Tokyo, Japan) at
the SFJ and in the GSV using a 5- to 10-MHz transducer.
Venous reflux was assessed while the patient was standing.
For evaluation of the SFJ, a pneumatic thigh cuff (Hokan-
son, Bellevue, Wash) was attached to the thigh, inflated to
80 mmHg, and then rapidly deflated. For evaluation of the
GSV, the transducer was placed 10 cm above knee level,
and a cuff was applied to the calf, inflated to 100 mm Hg,
and then rapidly deflated. The diameter of the GSV was
measured in cross-sectional view 3 to 4 cm distal to the SFJ
with the patient standing. Venous reflux was considered to
be present if the RT 0.5 seconds.
The details of the NIRS examination protocol have
been described previously.14,16-18 The light source of the
device (OM-200; Shimadzu Co, Kyoto, Japan) consists of
three laser beams with different wavelengths (780, 805,
Fig 1. The near-infrared spectroscopy examination asse
venous blood-filling index (FI-HHb) was calculated by
time taken to fill 90% of the venous volume (HHbFT9
perform (c) one tiptoemovement with weight-bearing on
then to return to the initial position, the changes inHHb
calculated as HHbEI HHbEV/HHbV. After a new p
movements, allowing venous expulsion (HHbE) and su
resting position. The venous retention index (RI-HHb)and 830 nm). According to the variations in optical density et each wavelength, O2Hb, HHb, and total Hb are calcu-
ated on the basis of the Lambert-Beer law,10 allowing
hanges in the concentration of Hb to be calculated. Our
nstrument had a probe containing the light source and two
eparate detectors fixed at 25 mm and 40 mm from the
ource. A review by McCully and Hamaoka19 has shown
hat light travels in a shallow arc to a penetration depth of
bout one-half the separation distance into the tissue. The
ight emitter-detector distance of the probe used in our
tudy was 40 mm, so the penetration depth was estimated
o be 20 mm. Changes in the hemoglobin concentration
ere expressed as absolute values in micromols per liter.
For assessment of ambulatory venous function, mea-
urements were carried out using the same standard exer-
ise protocol as that for air plethysmography (Fig 1). The
ensor was placed firmly on the posterior aspect of the calf,
ver the medial head of the gastrocnemius muscle, using
dhesive tape. The patient rested supine initially for 5
inutes with the leg elevated on a foam block. The patient
hen stood without putting any weight on the leg being
tudied, resulting in an increase of HHb concentration as
he veins filled. The patient was then asked to keep still until
n HHb volume (HHbV) plateau had been reached. The
alf venous blood-filling index (FI-HHb; mol/L/s) was
alculated by dividing 90% of the venous blood volume
HHbV) by the time taken to fill 90% of the venous
olume. Then, the patient was asked to perform one tiptoe
ovement with weight-bearing on both legs, which pro-
uced an ejected volume (HHbEV), and then return to the
nitial position, the change in HHb being observed. The
alf venous ejection index (EI-HHb) was calculated as
HbEI  HHbEV/HHbV.
After a new plateau had been reached, the patient was
sked to perform 10 tiptoe movements to achieve venous
arious deoxygenated hemoglobin (HHb) variables. Calf
ng 90% of the venous blood volume (HHbV90) by the
ter (a) resting, the patient was asked to (b) stand and
legs, which produced an ejected volume (HHbEV), and
observed. The calf venous ejection index (EI-HHb) was
had been reached, the patient performed (d) 10 tiptoe
uent retention (HHbR), and then returned to the (e)
etermined as HHbRI  HHbR/HHbE.sses v
dividi
0). Af
both
being
lateau
bseqxpulsion (HHbE) and a subsequent retention (HHbR).
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Volume 56, Number 6 Yamaki et al 1651The venous retention index (RI-HHb) was determined as
HHbRIHHbR/HHbE. Our previous study had shown
that the combination of FI0.2 and RI2.9 improved the
ability to discriminate early from advanced CVI, wth a
sensitivity of 94% and a specificity of 86%.17
UGFS procedure. The sclerosant foam was prepared
by Tessari’s method using 1% or 3% POL (Polidocasclerol;
Zeria Pharmaceutical Co Ltd, Tokyo, Japan). Details of the
methods used for foam sclerotherapy were described previ-
ously.20 The patients were placed supine with their affected
leg elevated 30°, and each visible varicose tributary vein was
injected first using 23-gauge butterfly needles. All patients
received0.5 mL POL foam per injection to minimize any
foam migration beyond the target vein.20 Subsequently 1%
or 3% POL-F was injected into the GSV under ultrasound
guidance using a 21-gauge venous catheter. The GSV
cannulae were inserted before injection of the tributaries.
The total amount of injected foam did not exceed 10mL in
any of the cases.21
After completion of foam sclerotherapy, compression
pads and elastic bandages were applied and kept on contin-
uously for the first 2 days. All patients were encouraged to
ambulate after the treatment. On day 3 after UGFS, the
elastic bandages and compression pads were removed, and
a class II thigh-high compression stocking was applied.
Follow-up after UGFS. To investigate the changes in
the values of calf muscle HHb, postsclerotherapy surveil-
lance was done at 3 months using NIRS. Duplex scanning
was done at 3months to evaluate the efficacy of UGFS. The
results of duplex ultrasound imaging were classified as
follows:
1. Complete occlusion: the GSV had shrunk and was oc-
cluded.
2. Partial GSV recanalization with no reflux.
3. Partial GSV recanalization with reflux.
4. Complete GSV recanalization with reflux.
The primary end point of this study was an evident im-
provement in calf muscle deoxygenation after UGFS. The
secondary end point was obliteration of the GSV.
Statistical analysis. All data were analyzed using SPSS
16.0 software (SPSS Inc, Chicago, Ill). Comparisons of
numerical data between groups of patients weremade using
Student t-test, and 2 contingency table analysis was used
to evaluate differences between proportions. Continuous
data are expressed as mean standard deviation. Statistical
significance was defined as P  .05.
RESULTS
Patient characteristics. Table I summarizes the base-
line characteristics of the two study groups, which did not
differ significantly in age (P  .587), the male-to-female
ratio (P  .889), or in height (P  .945), weight (P 
.555), or body mass index (P  .430). The mean GSV
diameter was 6.5  1.5 mm for the 1% POL-F group and
6.9  1.6 mm for the 3% POL-F group, which was not
significantly different (P .181). There was also no signif-
icant intergroup difference in each CEAP class (C2, P  u630; C3, P  .836; C4a, P  .554), with 79.2% of 1%
OLF-F patients and 83.3% of 3% POL-F patients at C2
uncomplicated varicose veins). Successful cannula place-
ent and ultrasound-monitored foam injection were ac-
omplished in all patients without any immediate compli-
ations.
Changes in NIRS-derived parameters before and
fter UGFS. NIRS after UGFS demonstrated significant
eductions in the levels of FI-HHb in both treated groups
P .039 and P .0001, respectively; Figs 2, A and 3, A)
nd significant reductions in the levels of RI-HHb (P 
0001, P  .008, respectively; Figs 2, C and 3, C). How-
ver, there was no significant difference in the levels of
I-HHb before and after UGFS (P  .250 and P  .084,
espectively; Figs 2, B and 3, B).
Outcome of UGFS. Table II reports the findings
btained by duplex ultrasound imaging 3 months after the
reatment. Complete occlusion was demonstrated in 56.3%
f the patients who received injections of 1% POL-F and in
6.7% of those who received injections of 3% POL-F, there
eing no significant difference in treatment outcome be-
ween the groups (P  .333). Similarly, 25.0% of the
atients who received 1% POL-F and 27.7% of those who
eceived 3% POL-F showed partial recanalization with no
eflux (P  .775). Patients who received 3% POL-F had a
igher success rate, but this was not statistically significant
P .076). In contrast, 18.7% of the patients who received
% POL-F showed reflux in the GSV 3 months after
reatment. Similarly, 5.6% of the patients in the 3% POL-F
roup showed reflux in the treated GSV.
ISCUSSION
This study investigated the effect of UGFS on calf
uscle deoxygenation in patients with superficial CVI. We
ound that 1% POL-F and 3% POL-F were as equally
ffective for the treatment of GSV reflux, with 79% of the
% POL-F group and 83% of the 3% POL-F group having
able I. Baseline characteristics of the patients receiving
% or 3% polidocanol foam (POL-F)
ariablesa
1% POL-F 3% POL-F
P(n 48) (n 36)
ge, year 64.7  8.9 66.3  8.8 .587
emale sex 34 (70.8) 26 (72.2) .889
eight, m 1.60  0.07 1.60  0.08 .945
eight, kg 56.7  10.6 59.2  9.4 .555
ody mass index, kg/m2 22.1  3.5 23.0  2.7 .430
SV diameter, mm 6.5  1.5 6.9  1.6 .181
EAP C classificationb
C2 38 (79.2) 30 (83.3) .630
C3 1 (2.1) 1 (2.8) .836
C4a 9 (18.7) 5 (13.9) .554
SV, Great saphenous vein.
Continuous data are shown as mean  standard deviation, and categoric
ata as number (%).
CEAP C classification: C2, varicose veins; C3, edema without skin changes;
4a, pigmentation or eczema.ncomplicated varicose veins (CEAP C2), and that there
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December 20121652 Yamaki et alwere significant reductions in the values of FI-HHb and
RI-HHb after UGFS but no significant changes in the value
of EI-HHb.
The safety and efficacy of UGFS as a minimally invasive
treatment for varicose veins has become widely accepted, and
a number of large case series have been reported.22-26 The use
of an appropriate concentration and volume of foam sclero-
sant yields good short-term GSV occlusion rates. At the Sec-
ond European Consensus Meeting on Foam Sclerotherapy
(ECMFS), most experts reported using 3% POL to prepare
foam for the treatment of GSV reflux.21
However, recent studies comparing 1% and 3% POL-F
found that the two concentrations were equally effective
when the GSV trunk diameter was 8 mm.27,28 Hamel-
Desnos et al27 reported that after 3 weeks, reflux was
abolished in 96% of patients who received 3% POL-F and in
88% of those who received 1% POL-F, with no significant
Fig 2. Changes in the near-infrared spectroscopy-deriv
before and after 1% polidocanol foam (POL-F) sclerothe
reduction in the level of the calf venous blood-filling inde
level of the calf venous ejection index (EI) before and aft
reduction in the level of the venous retention index (RI)intergroup difference in the success rate. Even after 2 years, deflux was absent in 69% of the 3% group and in 68% of the
% group, the success rate again showing no significant
ntergroup difference.27
Similarly, Blaise et al28 found that at 6 months, venous
eflux was abolished in 69% of patients who received 1%
OL-F and in 85% of those who received 3% POL-F; the
orresponding figures at 3 years were 79% and 78%, respec-
ively. The authors thus concluded that 1% and 3% POL-F
ad equivalent efficacy for treatment of GSV incompe-
ence.28
Nevertheless, Ceulen et al29 suggested that there was a
linically relevant, but nonsignificant, difference between
% and 3% POL-F in the proportion of patients achieving
SV occlusion (69.5% vs 80.1%). After 1 year of follow-up,
hey concluded that the use of 3% POL-F was more effec-
ive in terms of absence of reflux and disappearance of
omplaints. In the present study, we found no significant
oxygenated hemoglobin (HHb) parameters are shown
A, Near-infrared spectroscopy demonstrated significant
; P .039). B, There was no significant difference in the
am sclerotherapy (P  .250). C, There was a significant
foam sclerotherapy (P  .0001).ed de
rapy.
x (FI
er foifference of effectiveness between 1% and 3% POL-F,
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and elimination of reflux. This suggests that 3% POL-Fmay
be a better sclerosant, even though POL-F at both 1% and
3% is effective for treatment of superficial venous insuffi-
Fig 3. Near-infrared spectroscopy-derived parameters
after 3% polidocanol foam (POL-F) sclerotherapy.A,Nea
the level of calf venous blood-filling index (FI; P .0001
venous ejection index (EI) before and after foam scleroth
level of venous retention index (RI) after sclerotherapy (
Table II. Outcome of ultrasound-guided foam
sclerotherapy with 1% or 3% polidocanol foam (POL-F)
Outcome
1% POL-F 3% POL-F
P
(n  48) (n  36)
No. (%) No. (%)
Occlusion 27 (56.3) 24 (66.7) .333
Partial recanalization with no reflux 12 (25.0) 10 (27.7) .775
Subtotal 39 (81.3) 34 (94.4) .076
Partial recanalization with reflux 9 (18.7) 2 (5.6) .076
Complete recanalization with reflux 0 0 . . .
Subtotal 9 (18.7) 2 (5.6) .076
Total 48 (100) 36 (100)ciency. cAlthough most studies have set the primary end point
f UGFS as obliteration or elimination of reflux, few have
nvestigated the functional outcome after foam sclerother-
py. Yamaki et al23 used air plethysmography to compare
unctional outcome betweenUGFS and ultrasound-guided
iquid sclerotherapy. They found that venous filling index
alues remained normal during subsequent follow-up after
GFS, whereas the venous filling index began to increase
fter ultrasound-guided liquid sclerotherapy and the differ-
nce was significant at 6 months (P .0005). At 9 months,
hey also found that there was a significant difference in the
esidual volume fraction between the two groups and that
he residual volume fraction continued to improve after
GFS (P  .033).
Brunken et al30 used photoplethysmography and
train-gauge plethysmography to investigate changes in
enous function after UGFS. They found a significant
ncrease in venous refilling time (P  .00003) and a de-
oxygenated hemoglobin (HHb) are shown before and
ared spectroscopy demonstrated significant reduction in
There was no significant difference in the level of the calf
(P .084). C, There was a significant reduction in the
.008).of de
r-infr
). B,
erapyrease in venous capacity (P  .0007) after UGFS.30 Sim-
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December 20121654 Yamaki et alilarly, Darvall et al31 used digital photoplethysmography to
show that the median venous refilling time improved sig-
nificantly after UGFS (P  .0005).31
Since the first observations of tissue oxygenation using
NIRS by Jöbsis,32 this technique has been subsequently
refined and applied to the study of cerebral hemodynam-
ics.33-38 By choosing an accurate distance between source
and detector, NIRS can provide direct measurements for
anymuscle of interest. During the last 2 decades, numerous
studies have developed and refined the NIRS approach for
studying skeletal muscular hemodynamics and metabolism
in vivo.39-43 Attempts have also been made to apply NIRS
to venous hemodynamics in patients with CVI. Hosoi et
al12 first applied this modality for assessment of hemody-
namics in patients with CVI. They used the ambulatory
venous RI obtained from the serial changes in HHb and
found that NIRS was useful for evaluation of ambulatory
venous dysfunction.12 Later, they studied patients with
symptomatic post-thrombotic syndrome and found that
the degree of ambulatory venous RI was correlated well
with clinical severity.13
We have previously investigated the correlation of clin-
ical severity and ultrasound-guided reflux parameters with
NIRS-derived parameters in patients with CVI. We found
that (1) FI and RI measured by NIRS were increased in
patients with advanced CVI, (2) EI measured by NIRS was
significantly reduced in patients with deep CVI alone com-
pared with superficial CVI alone, (3) ultrasound-derived
PRV showed a better positive correlation with NIRS-
derived RI in the SFJ, GSV, and popliteal vein and with EI
in the gastrocnemius vein, and (4) a combination of FI
0.2 and RI 2.9 significantly improved the ability to
discriminate early from advanced CVI.17
It was of interest that we found a poor correlation
between NIRS-derived parameters and ultrasound-derived
RT. NIRS-derived RI appeared to better reflect the severity
of venous reflux and was vastly superior to ultrasound-
guided RT. This was further supported by the observation
that NIRS-derived RI was significantly correlated with
ultrasound-derived PRV, which is regarded as a useful
parameter for discrimination of clinical severity. Among the
parameters evaluated in the present study, NIRS-derived FI
and RI appeared promising for assessing the effects of
UGFS in patients with superficial CVI. Furthermore, we
found that increased RI was predictive of the development
of post-thrombotic syndrome in patients with a first epi-
sode of deep vein thrombosis.16,17 Follow-up for a much
longer period may reveal whether increased calf muscle
deoxygenation after UGFS is predictive of varicose vein
recurrence.
Our study had some potential limitations. In particular,
the 3-month follow-up period was too short to allow a full
evaluation of the efficacy of UGFS. In addition, the limited
sample size could have introduced a type II statistical error.
Finally, repetitive examinations may be required to confirm
the usefulness of NIRS for follow-up of patients receiving
UGFS.
1ONCLUSIONS
NIRS after foam sclerotherapy demonstrated signifi-
ant reductions in the levels of FI and RI in patients treated
ith 1% POL-F or 3% POL-F. Measurement of these
arameters by NIRS was simple and noninvasive, and was
ble to indicate functional improvement after foam sclero-
herapy in patients with superficial venous insufficiency.
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